Biopharma savings from avoiding "hot" M&A targets at peak$NBIX $5B$BLUE $5B$PBYI $4B$CLVS $3.5B$EXEL $3B$ACAD $2.5B$PTLA $2.5B$RDUS $2.5B$ONCE $2B$SGYP $2B

Biopharma savings from avoiding "hot" M&A targets at peak $NBIX -$5B $BLUE -$5B $PBYI -$4B $CLVS -$3.5B $EXEL -$3B $ACAD -$2.5B $PTLA -$2.5B $RDUS -$2.5B $ONCE -$2B $SGYP -$2B

09:01 EST 12 Dec 2018 | Andy Biotech

Biopharma savings from avoiding "hot" M&A targets at peak $NBIX -$5B $BLUE -$5B $PBYI -$4B $CLVS -$3.5B $EXEL -$3B $ACAD -$2.5B $PTLA -$2.5B $RDUS -$2.5B $ONCE -$2B $SGYP -$2B

More From BioPortfolio on "Biopharma savings from avoiding "hot" M&A targets at peak $NBIX -$5B $BLUE -$5B $PBYI -$4B $CLVS -$3.5B $EXEL -$3B $ACAD -$2.5B $PTLA -$2.5B $RDUS -$2.5B $ONCE -$2B $SGYP -$2B"